Charter Oak Capital Management’s aTyr Pharma ATYR Stock Holding History

Charter Oak Capital Management’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-150	Closed	–	–	935
2022 Q2	$0	Hold	150	–	–	﹤0.01%	1037
2022 Q1	$1K	Hold	150	–	–	﹤0.01%	949
2021 Q4	$1K	Hold	150	–	–	﹤0.01%	837
2021 Q3	$1K	Buy	+150	New	+$897	﹤0.01%	811

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Charter Oak Capital Management's ATYR Position: Q3 2022 in Review

Charter Oak Capital Management sold out of aTyr Pharma (ATYR) in Q3 2022, closing a stake of 150 shares.

Charter Oak Capital Management first reported a position in ATYR in Q3 2021 and held it in 4 quarters. The position peaked at $1K in Q1 2022. 33 funds tracked by Wall St. Rank hold ATYR as of Q3 2022.

Charter Oak Capital Management reported no remaining aTyr Pharma position as of Q3 2022 after selling out during the quarter.
Charter Oak Capital Management sold 150 aTyr Pharma shares in Q3 2022.
Charter Oak Capital Management first reported a position in aTyr Pharma in Q3 2021 and held it in 4 quarters.
Charter Oak Capital Management's aTyr Pharma position peaked at $1K in Q1 2022.
33 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2022.

Based on Charter Oak Capital Management's 13F filing for Q3 2022, filed 6 Dec 2022.